Massive potential overhang of 336% of outstanding shares creates severe downward pressure. Monitor for any early warrant exercises or selling by major holders like BVF and RA Capital. The common warrants expire 30 trading days after ENSURE topline data — a binary catalyst that could trigger a wave of selling regardless of trial outcome.
Price Chart
Executive Summary
Immunic filed Amendment No. 1 to its S-3 shelf registration to register the resale of up to 45,815,180 shares of common stock by selling stockholders, adjusting share counts for a 1-for-10 reverse stock split that became effective April 27, 2026. The shares are issuable upon exercise of pre-funded and common warrants issued in a February 2026 private placement that raised approximately $200 million in gross proceeds. The resale shares represent approximately 336% of current outstanding common stock, creating massive potential overhang.
Key Financial Metrics
Key Facts
- Up to 45,815,180 shares registered for resale (post-reverse split), representing ~336% of current 13,621,526 shares outstanding
- Shares issuable upon exercise of pre-funded warrants (exercise price $0.001/share) and common warrants (exercise price $8.73220/share)
- February 2026 private placement raised ~$200M in gross proceeds; aggregate warrant exercise price is also ~$200M
- Reverse stock split of 1-for-10 effective April 27, 2026
- Company will not receive any proceeds from resale of shares by selling stockholders
- Selling stockholders include BVF Entities, RA Capital, abrdn, Coastlands, Vivo, Janus, Commodore Capital, TCG Crossover, and others
- Top-line data from Phase 3 ENSURE trials expected by end of 2026
- Common warrants expire 30 trading days after topline data announcement, or February 17, 2031
Financial Impact
Potential dilution of up to 336% of current shares outstanding; ~$200M aggregate warrant exercise price if all exercised for cash
Risk Factors
- 336% dilution overhang could crush share price as selling stockholders monetize positions
- Warrant holders may sell aggressively ahead of ENSURE topline data expiration trigger
- Company receives no proceeds from resale — no offsetting capital benefit
- Reverse stock split may reduce liquidity and attract retail selling pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193805-26-000550 |
| Document: e665413_ex5-1.htm | 0001193805-26-000550 |
| Document: e665413_ex23-1.htm | 0001193805-26-000550 |
| Document: 0001193805-26-000550-index-headers.html | 0001193805-26-000550 |
| Document: 0001193805-26-000550-index.html | 0001193805-26-000550 |
| Document: 0001193805-26-000550.txt | 0001193805-26-000550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $12.19 | awaiting T+60 | — | $7.41 (−39.21%) |
Aug 11, 2026 10w ago | 8-K | $15.48 | awaiting T+60 | — | $7.41 (−52.13%) |
Jul 14, 2026 14w ago | 8-K | $14.69 $7.63 | ▼ −48.06% | ▼ −51.44% | $7.41 (−49.56%) |
Jun 29, 2026 17w ago | 8-K | $15.37 $9.37 | ▼ −39.04% | ▼ −42.60% | $7.41 (−51.79%) |
May 19, 2026 22w ago | 3 | $11.55 $16.06 | ▲ +39.05% | ▲ +34.04% | $7.41 (−35.84%) |
May 19, 2026 22w ago | 8-K | $11.60 $16.58 | ▲ +42.93% | ▲ +36.64% | $7.41 (−36.12%) |
Apr 30, 2026 25w ago | S-3/A | $9.65 $13.34 | ▼ −38.24% | ▼ −35.17% | $7.41 (+23.21%) |
Apr 23, 2026 26w ago | 8-K | $9.18 $15.00 | ▲ +63.40% | ▲ +58.38% | $7.41 (−19.28%) |
Apr 14, 2026 27w ago | 8-K | $11.10 $14.77 | ▲ +33.06% | ▲ +24.93% | $7.41 (−33.24%) |
Apr 10, 2026 28w ago | 8-K | $12.20 $14.77 | ▲ +21.07% | ▲ +12.14% | $7.41 (−39.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers